anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Aida

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 3,551
Current window 2,161-2,190
Pages 119
Rows per page 30
Arc: Aidaclear collectionreset all
18 30 60

Arc

2,161-2,190 of 3,551

filter-aware
05
Deezer | Results Presentation Deck | 19 slidesDeezer | Results Presentation Deck | 19 slides · Deezer
Conference presentation Investor relations Beat · AttentionLoop · Aha Moment1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
31
Includes FDA approval precedents in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
32
The diagram illustrates a classic dose-escalation study design.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
33
The slide uses a mix of expert quotes and a comparative table of clinical trials to validate the outpatient therapy thesis.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
34
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
35
Includes scientific diagrams of molecular pathways and efficacy charts.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
36
Slide contains three distinct data visualizations comparing IMX-110 against standard of care or historical benchmarks.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
37
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
38
Includes survival curves, median survival comparison, and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
39
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
40
Includes waterfall chart for best percentage change and line charts for longitudinal tumor size tracking against PD/PR thresholds.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
43
Includes logos for BeiGene and Novartis at the bottom.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
44
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
45
The slide uses a process-flow style layout to connect platform capabilities to specific therapeutic assets.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
46
The slide uses a process-like structure to map the platform pillars to specific product outputs.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
47
Includes technical diagrams of the drug molecule, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
48
Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
49
The slide uses a combination of mechanism-of-action diagrams and clinical/preclinical data charts to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
50
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
51
The slide is divided into two sections: ImmixBio Clinical Advisory Board and Select Nexcella Scientific Advisory Board Members.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
52
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
53
The slide is organized into two rows, one for each board, featuring headshots, names, titles, and associated company logos.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
55
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
57
The slide uses a bar chart to compare two groups of oncology drugs, highlighting a significant revenue disparity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
The slide uses a bar chart comparison to benchmark existing market leaders against placebo outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit